Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 224

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 8
Chunk 224
---
BOLT BIOTHERAPEUTICS, INC. 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS 

    Page

    Report of Independent Registered Public Accounting Firm (PCAOB ID 238)
     
    88

    Consolidated Balance Sheets
     
    89

    Consolidated Statements of Operations and Comprehensive Loss
     
    90

    Consolidated Statements of Stockholders’ Equity
     
    91

    Consolidated Statements of Cash Flows
     
    92

    Notes to the Consolidated Financial Statements
     
    93

87

Table of Contents

 Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Bolt Biotherapeutics, Inc.

Opinion on the Financial StatementsWe have audited the accompanying 2024 consolidated financial statements of Bolt Biotherapeutics, Inc. and its subsidiary  and the 2023 financial statements of Bolt Biotherapeutics, Inc. (collectively referred to as the “Company”), which comprise the balance sheets as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, of stockholders’ equity and of cash flows for the years then ended, including the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt About the Company's Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred net losses and negative cash flows from operations since inception, has an accumulated deficit and anticipates continuing to incur net operating losses and negative cash flows from operations for the foreseeable future that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be